VEGF165 Recombinant Rabbit mAb (SDT-3855-36)

Vascular Endothelial Growth Factor A (VEGFA) is a pivotal biomarker in clinical diagnosis, primarily valued for its central role in angiogenesis and disease progression. As a key regulator of new blood vessel formation, its expression is frequently dysregulated in numerous pathologies, especially solid tumors.

In oncology, elevated VEGFA levels in serum or tumor tissues strongly correlate with tumor growth, metastasis, and poor prognosis, making it a critical prognostic indicator. For example, in non-small cell lung cancer, VEGFA expression helps predict disease progression and assess patient outcomes. Beyond diagnosis, it serves as a predictive biomarker for anti-angiogenic therapies, such as bevacizumab, enabling personalized treatment strategies.

Moreover, VEGFA’s diagnostic significance extends to non-neoplastic conditions, including cardiovascular diseases, diabetic retinopathy, and inflammatory disorders, where aberrant angiogenesis contributes to pathogenesis. Its detection, via immunohistochemistry or liquid biopsies, offers a minimally invasive means of disease monitoring. In summary, VEGFA is an indispensable tool in clinical diagnostics, linking disease detection, prognosis, and therapeutic guidance.